AffordableGLP-1Providers Take the quiz
Guide · updated 2026-11-20

FDA warning letters and recalls: the lookup guide

Released: · Last reviewed:

Last verified 2026-11-20 · methodology · conflict-of-interest disclosure · dataset: open JSON

Straight answer: this page teaches the lookups — FDA’s warning-letter database, recall listings, and MedWatch — and records our desk’s tracking policy. We record only actions we have read on fda.gov: as of November 20, 2026 our files list FDA warning letters to three telehealth programs we track (NexLife, Eden and MEDVi) and to one compounding pharmacy (Empower), listed below. That is a statement about our records, not an all-clear for any other program. FDA’s active GLP-1 concern areas — unapproved salt forms, compounding dosing errors, fraudulent and counterfeit product — are exactly the checks built into our legitimacy checklist. Last verified 2026-11-20.

Warning letters and recalls on our records (November 20, 2026)

FDA actions involving compounded GLP-1s that we have read on fda.gov, newest first (read November 20, 2026)
DateRecipientActionWhat FDA said
2026-10-30 (posted 11-03)RonanRxWarning letter 737905“FDA-Approved Compounded Medications” category, labels naming RonanRx as compounder, “American made” and “$78 a month” video claims
2026-10-30Victory Medical Center Pharmacy (TX)Class II recall (FDA enforcement report, November 11)Semaglutide and tirzepatide combination vials; lack of processing controls; CO, FL, TX
October 2026Carolina Infusion, Apothecary Pharma, Houston RxClass II recalls (enforcement reports, October 14 and 21)Lack of assurance of sterility
2026-09-18Empower Pharmacy (TX)Warning letter 738238Additive tirzepatide and semaglutide products “essentially copies” of approved drugs; insanitary conditions
2026-06-08NexLifeWarning letter 730096Website claims false or misleading; labels named NexLife as if it compounded the drugs
2026-06-08EdenWarning letter 728279Labels named Eden as if it compounded the drugs; suppliers called “FDA-licensed”
2026-02-20MEDViWarning letter 721455Labels named MEDVi as compounder; “same active ingredient” claims

Telehealth warning letters to other programs in our dataset

FDA’s warning-letter index listed 114 telehealth warning letters when we read it on November 20, 2026: 56 dated in 2026 for false or misleading claims and 58 dated September 9, 2025, about unlawful online sales of unapproved and misbranded drugs. None had a close-out letter posted. Besides NexLife, Eden and MEDVi above, these went to programs in our dataset:

FDA telehealth warning letters to programs in our dataset (FDA warning-letter index, read November 20, 2026)
DateProgramLetter (source)FDA subjectClose-out
2026-06-08OrderlyMedsWarning letter 728291False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20Ivim HealthWarning letter 721816False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20Zappy HealthWarning letter 717991False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20Strut HealthWarning letter 721448False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20SkinnyRxWarning letter 717989False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20LevityWarning letter 717990False & Misleading Claims/Misbranded (Telehealth)none posted
2026-02-20Fifty 410Warning letter 721481False & Misleading Claims/Misbranded (Telehealth)none posted
2025-09-09Hims (Hims & Hers)Warning letter 716567Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09Hers (Hims & Hers)Warning letter 716825Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09ZealthyWarning letter 716501Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09Sprout HealthWarning letter 715879Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09Direct MedsWarning letter 716822Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09Remedy MedsWarning letter 716830Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted
2025-09-09CurexWarning letter 716821Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)none posted

Our analysis of the RonanRx letter: what FDA’s RonanRx letter says about a $78 price.

A warning letter is FDA’s notice of alleged violations with a deadline to respond; it is not a court finding, a recall or a ban. Check for a close-out letter before treating it as resolved.

The three lookups that answer it yourself

Warning letters: FDA’s searchable warning-letter database — search the pharmacy or company name, read the letter itself (subject lines tell you if it’s sterility, misbranding, or unapproved-drug marketing). Recalls: FDA’s recall and safety-alert listings, searchable by drug name — match lot numbers against your vial. Adverse events: MedWatch, both to search signals and to report your own (1-800-FDA-1088) — reporting is the feedback loop.

FDA’s current GLP-1 concern areas, per its own statements

Unapproved salt forms (semaglutide sodium/acetate) marketed as semaglutide; dosing errors from unit-conversion confusion across compounded concentrations — the reason this site refuses to publish a units calculator; fraudulent and counterfeit product, especially “brand” pens at implausible prices; and mass-marketed “research” peptides (retatrutide included) sold outside any lawful human-use pathway. Each maps to a bright-line test on the legitimacy checklist.

The verified adverse-event figures — with the caveat welded on

As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide — and FDA itself cautions that reports may be underreported and that a report does not by itself establish that the drug caused the event. Both figures were verified against FDA’s unapproved-GLP-1 concerns page on 2026-08-25. Quote them with the date and the causation caveat, or not at all.

What this desk records, and the standard for publishing it

When an enforcement action names a provider or pharmacy in our dataset, it gets recorded on that provider’s file with a link to the primary FDA document and a date — primary source or it doesn’t publish. This page updates as the dataset does; a blank ledger today means “nothing sourced yet,” never “nothing exists.”

Update log
  • 2026-08-26 — Page created per the Pass-12 audit; sources inline.

Researched By

Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.